← Leaderboards
Jerald P Radich
Fred Hutchinson Cancer Research Center
$16,007,933
Attributed
$22,252,356
Total exposure
11
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2005–23$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$22,252,356 · 11
By mechanism
R01$10,413,197 · 4
U10$3,407,309 · 1
R44$2,539,870 · 1
P01$2,377,875 · 3
UG1$1,963,320 · 1
U01$1,550,785 · 1
Top collaborators
- Clara D Bloomfield6 shared
- Daniel T Chiu5 shared
- Guido Marcucci5 shared
- Amy Paguirigan5 shared
- Levi Alexander Garraway4 shared
- Jesse J Salk4 shared
- John C Byrd2 shared
Most similar at Fred Hutchinson Cancer Research Center
Same institution · by research overlap
- George Earl Georges$15,152,269
- Vivian G Oehler$2,440,128
- Peter Chen$9,773,503
- Rainer F. Storb$23,835,935
- Kristin J Lastwika$1,362,196
Others in their field
Top investigators on “Leukemia”
- Richard K. Wilson · Washington University$209,620,938
- David Heimbrook · Leidos Biomedical Research, Inc.$168,419,678
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,967,203
- Peter C Adamson · National Childhood Cancer Foundation$143,910,899
- Ralph Parchment · Leidos Biomedical Research, Inc.$141,315,269
- Richard L Schilsky · University Of Chicago$129,102,207
Research focus
LeukemiaGene ExpressionSamplingMolecularMutationRelapseGeneticResponseResistanceCellsClinical TrialsResearch PersonnelDiagnosticMalignant NeoplasmsTumorCancer TypeClinical ResearchPathway InteractionsFlow CytometryHeterogeneityLaboratoriesMonitorAcute Myelocytic LeukemiaBase
Grant awards (53)
Understanding and predicting relapse in acute myeloid leukemia$409,640
R01 · FY2023 · CA · contact PI
Developing Bioinformatic and Microfluidic Single Cell Methods for Studying Intratumoral Heterogeneity in Acute Myeloid Leukemia$480,193
R01 · FY2022 · CA
Understanding and predicting relapse in acute myeloid leukemia$409,640
R01 · FY2022 · CA · contact PI
Developing Bioinformatic and Microfluidic Single Cell Methods for Studying Intratumoral Heterogeneity in Acute Myeloid Leukemia$134,571
R01 · FY2022 · CA
Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing$859,730
R44 · FY2021 · CA
ITSC for Leukemia: Novel Molecular strategies for NCTN "Individualized" Therapies$481,070
UG1 · FY2021 · CA
Developing Bioinformatic and Microfluidic Single Cell Methods for Studying Intratumoral Heterogeneity in Acute Myeloid Leukemia$377,311
R01 · FY2021 · CA
ITSC for Leukemia: Novel Molecular strategies for NCTN "Individualized" Therapies$719,943
UG1 · FY2020 · CA
Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing$690,175
R44 · FY2020 · CA
Developing Bioinformatic and Microfluidic Single Cell Methods for Studying Intratumoral Heterogeneity in Acute Myeloid Leukemia$615,257
R01 · FY2020 · CA
Understanding and predicting relapse in acute myeloid leukemia$364,998
R01 · FY2020 · CA · contact PI
Understanding and predicting relapse in acute myeloid leukemia$53,002
R01 · FY2020 · CA · contact PI
ITSC for Leukemia: Novel Molecular strategies for NCTN "Individualized" Therapies$762,307
UG1 · FY2019 · CA
Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing$690,175
R44 · FY2019 · CA
Developing Bioinformatic and Microfluidic Single Cell Methods for Studying Intratumoral Heterogeneity in Acute Myeloid Leukemia$634,257
R01 · FY2019 · CA
Understanding and predicting relapse in acute myeloid leukemia$405,460
R01 · FY2019 · CA · contact PI
ITSC for Leukemia: Novel Molecular Strategies for NCTN: "Individualized" Therapie$684,551
U10 · FY2018 · CA
Understanding and predicting relapse in acute myeloid leukemia$418,000
R01 · FY2018 · CA · contact PI
Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing$299,790
R44 · FY2018 · CA
ITSC for Leukemia: Novel Molecular Strategies for NCTN: "Individualized" Therapie$643,941
U10 · FY2017 · CA
Single-Cell Methods for Analysis of Clonal Heterogeneity and Evolution in Cancer$579,042
R01 · FY2017 · CA · contact PI
The Genetics of Post-Transplant Relapse in Myeloid Malignancy$365,200
R01 · FY2017 · CA · contact PI
ITSC for Leukemia: Novel Molecular Strategies for NCTN: "Individualized" Therapie$687,345
U10 · FY2016 · CA
Single-Cell Methods for Analysis of Clonal Heterogeneity and Evolution in Cancer$585,953
R01 · FY2016 · CA · contact PI
The Genetics of Post-Transplant Relapse in Myeloid Malignancy$365,200
R01 · FY2016 · CA · contact PI
Molecular Diagnostics$135,000
P01 · FY2016 · CA · contact PI
ITSC for Leukemia: Novel Molecular Strategies for NCTN: "Individualized" Therapie$691,472
U10 · FY2015 · CA
Single-Cell Methods for Analysis of Clonal Heterogeneity and Evolution in Cancer$583,874
R01 · FY2015 · CA · contact PI
The Genetics of Post-Transplant Relapse in Myeloid Malignancy$365,200
R01 · FY2015 · CA · contact PI
Molecular Diagnostics$135,000
P01 · FY2015 · CA · contact PI
ITSC for Leukemia: Novel Molecular Strategies for NCTN: "Individualized" Therapie$700,000
U10 · FY2014 · CA
Single-Cell Methods for Analysis of Clonal Heterogeneity and Evolution in Cancer$573,794
R01 · FY2014 · CA · contact PI
The Genetics of Post-Transplant Relapse in Myeloid Malignancy$354,244
R01 · FY2014 · CA · contact PI
Molecular Diagnostics$130,950
P01 · FY2014 · CA · contact PI
Single-Cell Methods for Analysis of Clonal Heterogeneity and Evolution in Cancer$646,486
R01 · FY2013 · CA · contact PI
The Genetics of Post-Transplant Relapse in Myeloid Malignancy$365,200
R01 · FY2013 · CA · contact PI
Molecular Diagnostics$126,900
P01 · FY2013 · CA · contact PI
Molecular Diagnostics$135,000
P01 · FY2012 · CA · contact PI
Resistance and Relapse in Chronic Myeloid Leukemia$354,401
P01 · FY2011 · CA · contact PI
Resistance and Relapse in Chronic Myeloid Leukemia$245,136
P01 · FY2010 · CA · contact PI
Resistance and Relapse in Chronic Myeloid Leukemia$274,568
P01 · FY2009 · CA · contact PI
Resistance and Relapse in Chronic Myeloid Leukemia$269,347
P01 · FY2008 · CA · contact PI
Genomic Analysis of Gene Copy Number in Thyroid Cancer$441,813
R01 · FY2007 · CA · contact PI
Resistance and Relapse in Chronic Myeloid Leukemia$225,130
P01 · FY2007 · CA · contact PI
Genomic Analysis of Gene Copy Number in Thyroid Cancer$443,254
R01 · FY2006 · CA · contact PI
Genomic Analysis of Gene Copy Number in Thyroid Cancer$441,608
R01 · FY2005 · CA
GENE EXPRESSION PROFILE OF PROGRESSION &RESPONSE IN CML$398,689
U01 · FY2003 · CA
GENE EXPRESSION PROFILE OF PROGRESSION &RESPONSE IN CML$391,215
U01 · FY2002 · CA
GENETIC MARKERS IN PROGNOSIS AND RESIDUAL DISEASE$0
P01 · FY2002 · CA
GENE EXPRESSION PROFILE OF PROGRESSION &RESPONSE IN CML$383,961
U01 · FY2001 · CA
DETECTION AND TREATMENT OF MINIMAL RESIDUAL DISEASE$0
P01 · FY2001 · CA
GENE EXPRESSION PROFILE OF PROGRESSION &RESPONSE IN CML$376,920
U01 · FY2000 · CA
DETECTION AND TREATMENT OF MINIMAL RESIDUAL DISEASE$346,443
P01 · FY2000 · CA